ENSPRYNG (satralizumab) is a humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor. IL-6 is a signalling protein, produced by immune cells in the body, believed to play a key role in the inflammation occurring in people with neuromyelitis optica spectrum disorder (NMOSD), leading to unpredictable and severe relapses.
Enspryng is currently approved in over 50 countries. This includes Japan, Canada, Switzerland and the European Union as the first and only approved subcutaneous medicine for both adults and adolescents with anti-aquaporin-4 (AQP4) antibody positive NMOSD, which can be used as a monotherapy or in combination with immunosuppressants. In the US it is the first and only FDA-approved medicine for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD that can be administered subcutaneously.
Enspryng was designed by Chugai using novel antibody recycling technology, which allows for longer duration of antibody circulation and maximum inhibition of IL-6 signalling, while minimising safety risks in a chronic disease setting.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.